{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:36:06Z","timestamp":1787020566808,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019559","name":"Carl von Ossietzky Universit\u00e4t Oldenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019559","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lipoprotein(a) [Lp(a)] is a known independent risk factor for cardiovascular disease, yet awareness and management remain limited. The psychosocial implications of elevated Lp(a)-levels have been poorly characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare cardiovascular outcomes and cardiovascular risk factor (CVRF) modification in individuals with normal vs. elevated Lp(a) levels, and to assess the impact of individualized prevention recommendations. For the first time, the individual psychological stress caused by Lp(a) is being surveyed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The ELITE study is a prospective, interventional cohort study conducted in north-western Germany. Participants were regularly assessed for CVRFs, including Lp(a), hypertension, dyslipidemia, diabetes mellitus, weight, nicotine \u2013 as well as lipoprotein (a), physical activity, dietary habits, depression and stress. They received written, personalized prevention recommendations. Follow-up averaged 4.4 years. Two groups were analyzed: Group 1 (Gr1, n=3,241) with normal Lp(a), and Group 2 (Gr2, n=841) with elevated Lp(a \u226575 nmol\/l).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Gr2 (mean Lp(a) 154.8 nmol\/l) and Gr1 (mean Lp(a) 16.4 nmol\/l) were comparable in age (~53 years) and sex distribution (~49% female). Most participants with elevated Lp(a) were previously unaware of their levels; 30% were referred to specialists, and ~40% reported concern or anxiety. Combined cardiovascular endpoints (CHD, stroke, heart failure, PAD, carotid stenosis, AF) occurred significantly more often in Gr2 (p&lt;0.001), despite similar CVRF profiles, except for higher baseline LDL-C in Gr2 (p&lt;0.001). Hypertension (61%) and physical inactivity (57%) were the most prevalent CVRFs. Personalized prevention measures led to significant improvements in blood pressure, LDL-C, smoking, physical activity, and weight in both groups. Lipid-lowering therapy improved markedly in Gr2 (12% to 23%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Elevated Lp(a) is associated with a significantly higher rate of cardiovascular events, independent of traditional CVRFs. This confirms a causal role of Lp(a) in CV morbidity. Personalized written prevention recommendations improved CVRFs across both groups, though further optimization is needed. Notably, elevated Lp(a) also imposes a psychosocial burden, underlining the need for enhanced education, counseling, and clinical pathways.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12944-025-02785-2","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T14:18:52Z","timestamp":1763129932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cardiovascular endpoints and psychosocial challenges of lipoprotein(a) of 5726 participants in the ELITE-study over 5 years"],"prefix":"10.1186","volume":"24","author":[{"given":"Bastian","family":"Schrader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Weers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Scorcelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"L\u00fcders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Vaske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Garstecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Els\u00e4sser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"2785_CR1","doi-asserted-by":"publisher","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL. Heart disease and stroke statistics\u20142023 update: a report from the American heart association. Circulation. 21. Februar 2023 [zitiert 24. Februar 2023];147(8). Verf\u00fcgbar unter:\u00a0https:\/\/www.ahajournals.org. https:\/\/doi.org\/10.1161\/CIR.0000000000001123.","DOI":"10.1161\/CIR.0000000000001123"},{"key":"2785_CR2","doi-asserted-by":"publisher","unstructured":"Djeundje VB, Haberman S, Bajekal M, et al. The slowdown in mortality improvement rates 2011\u20132017: a multi-country analysis. Eur Actuar J. 2022;12:839\u201378. https:\/\/doi.org\/10.1007\/s13385-022-00318-0.","DOI":"10.1007\/s13385-022-00318-0"},{"issue":"20","key":"2785_CR3","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1093\/eurheartj\/ehx033","volume":"38","author":"B Gencer","year":"2017","unstructured":"Gencer B, Kronenberg F, Stroes ES, Mach F. Lipoprotein(a): the revenant. Eur Heart J 21 Mai. 2017;38(20):1553\u201360.","journal-title":"Eur Heart J 21 Mai"},{"issue":"8","key":"2785_CR4","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1194\/jlr.R067314","volume":"57","author":"K Schmidt","year":"2016","unstructured":"Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016;57(8):1339\u201359.","journal-title":"J Lipid Res"},{"key":"2785_CR5","doi-asserted-by":"publisher","unstructured":"Mach E, Koskinas KC, Roeters van Lennep JE, Tokg\u00f6\u00f6zo\u011f\u011flu L, Badimon L, Baigent C, et al.\u00a0Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: developed by the task force for the management of dyslipidaemias of\u00a0the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2025.\u00a0https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190.","DOI":"10.1093\/eurheartj\/ehaf190"},{"key":"2785_CR6","doi-asserted-by":"crossref","unstructured":"Surma S, Sosnowska B, Reiner \u017d, Banach M. New data allow to better understand the secrets of lipoprotein(a): is that for sure?. Eur Heart J Open. 31. August 2024 [zitiert 12. Juli 2025];4(5). Verf\u00fcgbarunter:\u00a0https:\/\/academic.oup.com\/ehjopen\/article\/doi\/10.1093\/ehjopen\/oeae066\/7745802.","DOI":"10.1093\/ehjopen\/oeae066"},{"key":"2785_CR7","doi-asserted-by":"crossref","unstructured":"Yeang C, Karwatowska-Prokopczuk E, Su F, Dinh B, Xia S, Witztum JL. u. a. Effect of Pelacarsen on lipoprotein(a) cholesterol and corrected Low-Density lipoprotein cholesterol. J Am Coll Cardiol. M\u00e4rz 2022;79(11):1035\u201346.","DOI":"10.1016\/j.jacc.2021.12.032"},{"key":"2785_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","volume":"287","author":"L Cho","year":"2025","unstructured":"Cho L, Nicholls SJ, Nordestgaard BG, Landmesser U, Tsimikas S, Blaha MJ. u. a. Design and rationale of Lp(a)HORIZON trial: assessing the effect of Lipoprotein(a) Lowering with Pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a). Am Heart J September. 2025;287:1\u20139.","journal-title":"Am Heart J September"},{"issue":"3","key":"2785_CR9","first-page":"222","volume":"333","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Ni W, Rhodes GM, Nissen SE, Navar AM, Michael LF. u. a. Oral Muvalaplin for Lowering of Lipoprotein(a): A randomized clinical trial. JAMA 21 Januar. 2025;333(3):222\u201331.","journal-title":"JAMA 21 Januar"},{"issue":"6","key":"2785_CR10","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1253\/circj.CJ-20-0051","volume":"84","author":"AY Jang","year":"2020","unstructured":"Jang AY, Han SH, Sohn IS, Oh PC, Koh KK. Lipoprotein(a) and cardiovascular diseases \u2015 revisited \u2015. Circ J 25 Mai. 2020;84(6):867\u201374.","journal-title":"Circ J 25 Mai"},{"issue":"24","key":"2785_CR11","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","volume":"128","author":"J Leebmann","year":"2013","unstructured":"Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D. u. a. Lipoprotein apheresis in patients with maximally tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 17 Dezember. 2013;128(24):2567\u201376.","journal-title":"Circulation 17 Dezember"},{"issue":"S1","key":"2785_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11789-017-0082-3","volume":"12","author":"R Klingel","year":"2017","unstructured":"Pro(a)LiFe-Study Group, Klingel R, Heibges A, Fassbender C. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German National guidelines. Clinical Research in Cardiology Supplements. 2017;12(S1):38\u201343.","journal-title":"Clinical Research in Cardiology Supplements"},{"issue":"23","key":"2785_CR13","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, Bor\u00e9n J, Andreotti F, Watts GF. u. a. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J Dezember. 2010;31(23):2844\u201353.","journal-title":"Eur Heart J Dezember"},{"issue":"11","key":"2785_CR14","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","volume":"36","author":"S Varvel","year":"2016","unstructured":"Varvel S, McConnell JP, Tsimikas S. Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States. Arterioscler Thromb Vasc Biol. 2016;36(11):2239\u201345.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2785_CR15","doi-asserted-by":"crossref","unstructured":"L\u00fcders S, Schrader B, B\u00e4secke J, Haller H, Els\u00e4sser A, Koziolek M. ELITE-Studie \u2013 Ern\u00e4hrung, Lebensstil und individuelle Information zur Verhinderung von Schlaganfall, Demenz und Herzinfarkt \u2013 Studiendesign und kardiovaskul\u00e4re Aufnahmedate. DMW - Dtsch Med Wochenschr [Internet]. 13. Dezember 2018 [zitiert 18. Januar 2019]; Verf\u00fcgbar unter:\u00a0http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-0714-3835.","DOI":"10.1055\/a-0714-3835"},{"issue":"12","key":"2785_CR16","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1097\/HJH.0000000000002588","volume":"38","author":"B Schrader","year":"2020","unstructured":"Schrader B, Schrader J, Els\u00e4sser A, B\u00fcnker AM, Hillmann B, Vaske B. u. a. Influence of cardiovascular risk factors on arterial hypertension and mild cognitive impairment in 4602 participants of the ELITE study. J Hypertens Dezember. 2020;38(12):2475\u201381.","journal-title":"J Hypertens Dezember"},{"issue":"4","key":"2785_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.21101\/cejph.a6908","volume":"29","author":"B Schrader","year":"2021","unstructured":"Schrader B, Schrader J, Koziolek M, Els\u00e4sser A, B\u00fcnker AM, Hillmann B. u. a. Influence of individualized prevention recommendations after one year on the control of hypertension in 3,868 follow-up participants of the ELITE study. Cent Eur J Public Health 31 Dezember. 2021;29(4):305\u201310.","journal-title":"Cent Eur J Public Health 31 Dezember"},{"issue":"4","key":"2785_CR18","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.31083\/j.rcm2204162","volume":"22","author":"B Schrader","year":"2021","unstructured":"Schrader B, Shakoor A, Schmidt A, Schrader J, Vaske B, Haller H. u. a. Relationship between Lipoprotein(a) and cardiovascular risk factors\u2014data from 4602 participants of the ELITE study. Rev Cardiovasc Med. 2021;22(4):1569.","journal-title":"Rev Cardiovasc Med"},{"issue":"01","key":"2785_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5414\/NHX02153","volume":"50","author":"B Schrader","year":"2021","unstructured":"Schrader B, L\u00fcders S, Els\u00e4sser A. Kardiovaskul\u00e4re Risikofaktoren Im alter Bei 4.602 teilnehmern der elitestudie. Nieren- Hochdruckkrankheiten 1 Januar. 2021;50(01):9\u201317.","journal-title":"Nieren- Hochdruckkrankheiten 1 Januar"},{"issue":"6","key":"2785_CR20","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas S. A test in context: Lipoprotein(a). J Am Coll Cardiol Februar. 2017;69(6):692\u2013711.","journal-title":"J Am Coll Cardiol Februar"},{"key":"2785_CR21","unstructured":"Brian A, Ference. LDL-Lowering to Specific Targets May Offset Risk From High Lp(a). In 2022 [zitiert 28. Februar 2023]. Verf\u00fcgbar unter:\u00a0https:\/\/www.medscape.com\/viewarticle\/974798#vp_2."},{"key":"2785_CR22","doi-asserted-by":"publisher","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","volume":"29","author":"KK Ray","year":"2023","unstructured":"Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C. u. a. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health - Eur Juni. 2023;29:100624.","journal-title":"Lancet Reg Health - Eur Juni"},{"issue":"21","key":"2785_CR23","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1016\/j.jacc.2022.09.021","volume":"80","author":"BS Hedegaard","year":"2022","unstructured":"Hedegaard BS, Bork CS, Kaltoft M, Klausen IC, Schmidt EB, Kamstrup PR. u. a. Equivalent impact of elevated Lipoprotein(a) and Familial hypercholesterolemia in patients with atherosclerotic cardiovascular disease. J Am Coll Cardiol November. 2022;80(21):1998\u20132010.","journal-title":"J Am Coll Cardiol November"},{"issue":"9","key":"2785_CR24","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/s41440-021-00668-4","volume":"44","author":"HH Liu","year":"2021","unstructured":"Liu HH, Cao YX, Jin JL, Hua Q, Li YF, Guo YL. u. a. Lipoprotein (a), hypertension, and cardiovascular outcomes: a prospective study of patients with stable coronary artery disease. Hypertens Res 1 September. 2021;44(9):1158\u201367.","journal-title":"Hypertens Res 1 September"},{"issue":"2","key":"2785_CR25","first-page":"352","volume":"80","author":"R Rikhi","year":"2023","unstructured":"Rikhi R, Bhatia HS, Schaich CL, Ashburn N, Tsai MY, Michos ED. u. a. Association of Lipoprotein(a) and hypertension in primary prevention of cardiovascular disease: the Multi-Ethnic study of atherosclerosis (MESA). Hypertens Dallas Tex 1979. Februar. 2023;80(2):352\u201360.","journal-title":"Februar"},{"issue":"14","key":"2785_CR26","first-page":"1093","volume":"273","author":"SN Blair","year":"1995","unstructured":"Blair SN. Changes in physical fitness and All-Cause mortality: A prospective study of healthy and unhealthy men. JAMA 12 April. 1995;273(14):1093.","journal-title":"JAMA 12 April"},{"issue":"9438","key":"2785_CR27","first-page":"937","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S, Hawken S, \u00d4unpuu S, Dans T, Avezum A, Lanas F. u. a. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 11 September. 2004;364(9438):937\u201352.","journal-title":"Lancet 11 September"},{"key":"2785_CR28","doi-asserted-by":"crossref","unstructured":"Schrader B, B\u00fcnker AM, Conradi C, L\u00fcders S, Vaske B, Koziolek M. Regular exercise is associated with a more favorable cardiovascular risk Profile, better quality of Life, less depression and less psychological stress. Int J Gen Med. Januar 2022;15:545\u201354.","DOI":"10.2147\/IJGM.S338496"},{"issue":"11","key":"2785_CR29","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1097\/HJH.0000000000002935","volume":"39","author":"B Schrader","year":"2021","unstructured":"Schrader B, Schrader J, Vaske B, Els\u00e4sser A, Haller H, del Vecchio. A, u. a. Football beats hypertension: results of the 3F (Fit&Fun with Football) study. J Hypertens November. 2021;39(11):2290.","journal-title":"J Hypertens November"},{"key":"2785_CR30","doi-asserted-by":"crossref","unstructured":"Schrader B, Weers A, Garmann B, L\u00fcders S, Scorcelletti M, Vaske B. Football as the champion of cardiovascular prevention: results of the randomized and interventional MY-3F study (Fit & fun with football after myocardial infarction or coronary artery disease). Eur J Prev Cardiol. 21. Mai 2025;zwaf273.","DOI":"10.1093\/eurjpc\/zwaf273"},{"issue":"11","key":"2785_CR31","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1161\/01.ATV.17.11.2783","volume":"17","author":"PN Hopkins","year":"1997","unstructured":"Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1997;17(11):2783\u201392.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2785_CR32","doi-asserted-by":"publisher","unstructured":"Hopkins PN, Hunt SC, Schreiner PJ, Eckfeldt JH, Borecki IB, Ellison CR, et al. Lipoprotein(a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease results from the NHLBI Family Heart Study.\u00a0Atheroscler. 1998;41(2):333\u201345.\u00a0https:\/\/doi.org\/10.1016\/s0021-9150(98)00174-9. PMID: 9862182.","DOI":"10.1016\/s0021-9150(98)00174-9"},{"key":"2785_CR33","first-page":"S68","volume":"76","author":"C \u00c1lvarez-Bueno","year":"2015","unstructured":"\u00c1lvarez-Bueno C, Cavero-Redondo I, Mart\u00ednez-Andr\u00e9s M, Arias-Palencia N, Ramos-Blanes R, Salcedo-Aguilar F. Effectiveness of multifactorial interventions in primary health care settings for primary prevention of cardiovascular disease: A systematic review of systematic reviews. 1 Juli. 2015;76:S68\u201375. Suppl Issue Health Promot Dis Prev Prim Health Care Focus Complex Multi-Risk Interv.","journal-title":"1 Juli"},{"issue":"3","key":"2785_CR34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1525-1497.2006.00331.x","volume":"21","author":"AH Christian","year":"2006","unstructured":"Christian AH, Mills T, Simpson SL, Mosca L. Quality of cardiovascular disease preventive care and physician\/practice characteristics. J Gen Intern Med M\u00e4rz. 2006;21(3):231\u20137.","journal-title":"J Gen Intern Med M\u00e4rz"},{"issue":"15","key":"2785_CR35","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1056\/NEJMoa2208681","volume":"387","author":"JS Lindholt","year":"2022","unstructured":"Lindholt JS, S\u00f8gaard R, Rasmussen LM, Mejldal A, Lambrechtsen J, Steffensen FH. u. a. Five-Year outcomes of the Danish cardiovascular screening (DANCAVAS) trial. N Engl J Med 13 Oktober. 2022;387(15):1385\u201394.","journal-title":"N Engl J Med 13 Oktober"},{"issue":"5","key":"2785_CR36","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/eurjpc\/zwab167","volume":"29","author":"NS Nurmohamed","year":"2022","unstructured":"Nurmohamed NS, Kaiser Y, Schuitema PCE, Ibrahim S, Nierman M, Fischer JC. u. a. Finding very high lipoprotein(a): the need for routine assessment. Eur J Prev Cardiol 5 Mai. 2022;29(5):769\u201376.","journal-title":"Eur J Prev Cardiol 5 Mai"},{"key":"2785_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","volume":"285","author":"G De Backer","year":"2019","unstructured":"De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner \u017d, Ryd\u00e9n L. u. a. Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis Juni. 2019;285:135\u201346.","journal-title":"Atherosclerosis Juni"},{"issue":"4","key":"2785_CR38","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.3390\/ijerph110404218","volume":"11","author":"S Schneider","year":"2014","unstructured":"Schneider S, Diehl K, Bock C, Herr R, Mayer M, G\u00f6rig T. Modifying health behavior to prevent cardiovascular diseases: A nationwide survey among German primary care physicians. Int J Environ Res Public Health 15 April. 2014;11(4):4218\u201332.","journal-title":"Int J Environ Res Public Health 15 April"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02785-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-025-02785-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02785-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T20:04:28Z","timestamp":1763150668000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-025-02785-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2785"],"URL":"https:\/\/doi.org\/10.1186\/s12944-025-02785-2","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"29 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This analysis was carried out with the financial support of Novartis Pharma GmbH. The responsibility for the content of the analysis and the interpretation of the results lies solely with the authors. The Novartis Pharma GmbH had no influence on the study design, data collection, data analysis or preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"362"}}